Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495910 · ClinicalTrials.gov registry record · Phase 1
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
A Phase 1 study of 21-Hydroxylase Deficiency, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 3
- Study locations
NCT01495910 is a Phase 1 study of 21-Hydroxylase Deficiency that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 6 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT01495910, a Phase 1 study of 21-Hydroxylase Deficiency, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency.
Conditions Studied
Interventions
- DRUG Abiraterone acetate
Study Locations (3)
Illinois
- - Chicago
Michigan
- - Ann Arbor
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01495910
The ClinicalTrials.gov registry entry for NCT01495910 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with 21-Hydroxylase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Abiraterone acetate is the first listed.
NCT01495910 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT01495910 about?
NCT01495910 is a clinical study titled "A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency". The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency.
What is the current status of trial NCT01495910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-12. Estimated completion is 2013-02.
What conditions does trial NCT01495910 study?
This clinical trial studies the following conditions: 21-Hydroxylase Deficiency.
What interventions are being tested in trial NCT01495910?
The interventions under investigation include: Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT01495910?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01495910 being conducted?
This trial has 3 study locations across Illinois, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for 21-Hydroxylase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.